Nexium I.V. (Esomeprazole)

Esomeprazole works by irreversibly inhibiting the H+/K+ ATPase enzyme, also known as the gastric proton pump, on the secretory surface of parietal cells. This inhibition blocks the final step of gastric acid production, leading to a sustained increase in gastric pH and allowing mucosal healing.

The appropriate dose of Nexium I.V. is determined by the prescribing clinician based on the patient’s specific condition, severity, renal and hepatic function, and other individual factors. Dosage regimens are not standardized in public literature and must follow the prescriber’s order.

Safety data for Nexium I.V. in pregnancy and lactation are limited. The product should only be used when the potential benefit justifies the potential risk to the fetus or infant. Clinicians should assess each case individually and discuss possible risks with the patient.

To order Nexium I.V., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Nexium I.V. contains esomeprazole, the S‑isomer of omeprazole, which offers more consistent plasma concentrations and may provide slightly greater acid suppression. Both belong to the proton pump inhibitor class, but esomeprazole is often preferred for intravenous use due to its predictable pharmacokinetics and rapid onset.

Nexium I.V. should be stored at ambient temperature, preferably below 25 °C, in its original container. The solution must be protected from light and moisture. Do not freeze the product, and use it within the expiry period indicated on the label.

Nexium I.V. is administered by slow intravenous infusion, typically over 30 to 60 minutes, under the supervision of qualified healthcare personnel. The exact infusion rate and duration are determined by the prescribing physician based on the clinical indication and patient characteristics.

Serious risks include Clostridioides difficile‑associated colitis, severe allergic reactions such as anaphylaxis, and rare but life‑threatening skin conditions like Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, hypersensitivity, and unexpected skin eruptions during therapy.

Nexium I.V. is contraindicated in patients with known hypersensitivity to esomeprazole or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, those on interacting medications such as clopidogrel, and patients for whom the risks of acid suppression outweigh the benefits.